Key Highlights
- Calyxo Inc. closes a $50 million Series D financing round, led by Avidity Partners, with notable contributions from Questa Capital and CRG.
- The company’s CVAC Aspiration System aims to minimize residual stone burden in kidney stone treatment, already benefiting over 1,300 patients in the U.S.
- Joe Catanese, President & CEO of Calyxo, emphasizes the potential of CVAC technology to transform kidney stone treatment despite challenging market conditions.
Source: Business Wire
Notable Quotes
- “We are excited about this round of funding which will further accelerate the company’s momentum,” – Joe Catanese, President & CEO at Calyxo Inc
- “Calyxo has an opportunity to alter the kidney stone treatment category and deliver a new generation of devices that can significantly improve care and comfort for millions of people afflicted by kidney stones,” – Jacob Garfield, Partner at Avidity Partners
SoH's Take
The recent funding milestone for Calyxo Inc. represents a significant step forward in the medical device industry, particularly in the realm of kidney stone treatment. The CVAC Aspiration System, with its innovative approach to minimizing residual stone burden, showcases a promising future in this medical sector. This funding not only underlines the confidence of investors like Avidity Partners, Questa Capital, and CRG in Calyxo’s technology but also reflects a growing trend towards more efficient, patient-friendly medical treatments. As we progress, such technologies are likely to become cornerstones in treating prevalent conditions like kidney stones, reducing the overall healthcare burden and improving patient outcomes.
